Lowest Price Guaranteed From USD 4,899
Over 30% of the total cost invested in developing a new drug can be saved by utilizing in silico services. However, this is highly variable and is dependent upon the nature of drug discovery projects
-- CEO, a US-based small-sized company
The computer aided drug discovery market is estimated to be worth $29 million in 2020 and is expected to grow at CAGR of 15.6% during the forecast period. The process of drug development, beginning from the discovery of a pharmacological lead to its commercial launch, is estimated to take around 10-15 years, involving capital investments in the range of USD 4-10 billion. Moreover, it is well-known that only a small proportion of leads, which are selected for further investigation during the initial stages of research, are actually translated into product candidates for clinical research studies. Over time, the complexities of drug discovery, have increased; this is especially true for large molecules, which are inherently more complex than conventional small molecule drugs. As a result, there has been a direct rise in overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector. Specifically, in 2019, the global R&D spending was estimated to be around USD 182 billion, with over 16,000 drug molecules reported to have been investigated. Presently, the industry is currently under tremendous pressure to identify ways to cope with rising capital requirements in drug discovery research and actively avoid losses owing to failed drug development programs. In addition, there has been an evident increase in regulatory stringency, which has made the drug approval process, especially for large molecules, significantly more difficult.
During the last several years, several computational drug discovery tools have been developed and introduced for enabling the identification, selection and optimization of pharmacological lead candidates. Currently, there are several computer aided drug discovery approaches available such as structure based drug design, fragment based drug discovery and ligand based drug discovery for multi-target drug design. The predictive power of these computational drug discovery tools has been proven to be very advantageous, allowing researchers to bypass the random screening of billions of molecules across hundreds of large molecule targets. According to industry experts, almost 35% of the total cost and time invested in developing a new drug can be saved by adopting computational drug discovery (CADD) approach. As a result, companies offering computer aided drug discovery services, such as computer-aided drug design (CADD), molecular modeling and quantitative structure–activity relationship (QSAR), have now become an important part of the pharmaceutical industry. In future, drug developers, especially those focused on the development of large molecules, are likely to continue relying on outsourcing for a significant part of their respective drug discovery and development operations. Owing to this, the computer aided drug discovery market is likely to witness substantial market growth during the forecast period.
Examples of key companies engaged in computer aided drug discovery market (which have also been profiled in this market report; the complete list of companies is available in the full report) include BioDuro, Creative Biostructure, GenScript, LakePharma, Abzena, BioNTech, Sygnature Discovery, ChemPartner, Sundia MediTech and Viva Biotech. This market report includes an easily searchable excel database of all the companies providing computer aided drug discovery services, worldwide.
Several recent developments have taken place in the field of computer aided drug discovery market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Computer Aided Drug Discovery Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)” market report features an extensive study on the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the computer aided drug discovery market. The market research report features an in-depth analysis, highlighting the capabilities of various industry stakeholders.
In addition to other elements, the market research report includes:
The key objective of computer aided drug discovery market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for computer aided drug discovery market during the forecast period. Based on several parameters, such as number of large molecules based drug discovery projects, adoption of in silico services for drug discovery and outsourcing profile, we have provided informed estimates on the likely evolution of the market for the forecast period 2020-2030. The market report also provides details on the likely distribution of the current and forecasted opportunity across [A] key step(s) of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization), [B] type of large molecule (antibodies, proteins, peptides, nucleic acids and vectors), [C] company size (small, mid-sized and large), [D] therapeutic area (autoimmune disorders, blood disorders, cardiovascular disorders, gastrointestinal and digestive disorders, hormonal disorders, HIV / AIDS, infectious diseases, metabolic disorders, mental disorders, musculoskeletal disorders, neurological disorders, oncological disorders, respiratory disorders, skin disorders, urogenital disorders and others), [E] type of clientele (pharmaceutical / biotechnology companies and academic / research institutes), and [F] key geographical regions (North America (the US and Canada), Europe (Italy, Germany, France, Spain and rest of Europe) and Asia-Pacific (China, India and Japan), along with the rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this market report were also influenced by inputs solicited via a survey and discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of discussions held with the following individuals (in alphabetical order):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.